Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Chemotherapy +/- PD-1 Inhibitor in Gastric/GEJ Cancer
NCT07132528Phase 4Not yet recruiting
- Sponsor
- Liaoning Medical Center
- Start
- Aug 2025
- Primary completion
- Mar 2028
01
Overview
Phase 4, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Liaoning Medical Center. Primary endpoint: Disease-Free Survival at 2 years. Planned start Aug 2025; status: not yet recruiting.
02
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07132528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132528.